Sep 27 |
Aclarion's Nociscan AI Plays Key Role in Advanced Understanding of Modic Changes
|
Sep 13 |
PRISM MarketView Showcases Aclarion: Disrupting Chronic Pain Treatment with Nociscan AI Technology
|
Sep 12 |
Aclarion Provides Corporate Update on Nociscan AI Technology Milestones
|
Sep 11 |
Investor Summit August 2024 Presentations Now Accessible for On-Demand Viewing
|
Sep 10 |
Aclarion Announces Completion of First Nociscan Exams in LIFEHAB Trial
|
Sep 6 |
Aclarion Added to PRISM Emerging Medical Devices Index
|
Sep 5 |
Aclarion Launches Surgeon Partnership to Apply Nociscan’s AI Technology to Personal Injury and Workers Compensation Market
|
Aug 29 |
Aclarion Launches Second Clinical Utility and Economic (CLUE) Trial Site With First Surgeon in New Jersey
|
Aug 21 |
Aclarion Launches the Clinical Utility and Economic (CLUE) Trial to Quantify How Often Nociscan’s AI Generated Biomarker Data Changes Surgical Treatment Plans
|
Aug 17 |
Aclarion Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
|